fink About - Profile | InvestorsHub

IHub Info
Membership Type:
Followed By:	629
Posts:	40,082
Boards Moderated:	4
Alias Born:	08/15/2009 05:26:01 PM

Personal Info
Age:	62
Location:	Dixie Tm4rs@yahoo is where I can be found.
Investment Philosophy:	Don't listen to me, I invest in penny stocks.
Occupation:	Looking.......well, sort of. NOT! Retired sky jockey. USAF Langley, Eastern, retired Delta. Now fly power and fuel lines across Dixie
Hobby:	Seeing another Sunrise or Sunset from 45,000 ft.
Favorite Links:	The 25 Axions OTC Bible.
Favorite Quote:	Just shut up and buy the book, The “Creature from Jekyll Island” and read it.
Person I'd Like to Meet:	Jesus Christ's girl friend, but not in a big hurry. Maybe in another 50+ years, Maybe another 70+ years, LOL I can wait on that met.
Favorite Movie:	Joe Dirt
Favorite Artist:	My kids
Favorite Team:	UGA Football...or Auburn...or BAMA...or any SEC Football. In that order
Default Signature:

Play Episode

8min

Proactive - Interviews for investors

Airtasker CEO on growth, AI & global expansion

Airtasker Ltd CEO Tim Fung talked with Proactive at AIM's Small and Midcap Conference about the company’s strategic focus across innovation, growth, and international expansion.** Fung outlined how Airtasker differentiates itself in the local services marketplace by operating as a community platform, where both customers and taskers set job scopes and pricing, rather than the company enforcing set rates. He emphasised Airtasker’s approach to worker empowerment, noting, *“The top people on our platform are running 150, 200 thousand dollars a year doing these kinds of jobs.”* Fung also acknowledged the challenges of the current consumer environment, pointing to Airtasker’s 14.8% revenue growth in the half as a result of lean operations and renewed brand investment. A key part of Airtasker’s strategy involves innovation across customer acquisition, user experience, and operational efficiency—highlighting its collaboration with OpenAI and use of AI tools like Copilot and Zendesk AI. Fung also discussed partnerships, including one with Visa Cash App Racing Bulls, as examples of how Airtasker showcases the diverse range of skilled work enabled by the platform. He concluded by outlining the investor case: a cash-generative, proven business model in Australia being used to fund international growth in the US and UK, offering upside potential with limited downside. #Airtasker #TimFung #ASX #GigEconomy #AIIntegration #MarketplacePlatform #SmallCapStocks #TechInnovation #FY25Strategy #ProactiveInvestors #OpenAI #GlobalExpansion #InvestorUpdates #StartupGrowth

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Proactive - Interviews for investors

Atrato Partners on Social Housing REIT (SOHO): strategy, debt and dividend outlook

Atrato Partners, the newly appointed Investment Manager of Social Housing REIT (SOHO) talked with Proactive's Stephen Gunnion about the current state of the specialised supported housing sector and how the company is tackling key challenges within its portfolio. Fund manager Adrian D'Enrico was joined by Michael Carey and Natalie Markham, offering a comprehensive update on SOHO’s operational and financial performance. D'Enrico addressed common misconceptions about the sector, clarifying that it is not temporary or homeless accommodation, but instead provides long-term homes for adults with care needs. “A misconception as well is that specialised supported housing is a passive investment based on the long lease,” he explained, underlining the importance of resident occupancy and the operational real estate nature of the assets. Carey detailed the steps taken to resolve issues with Parasol and My Space Housing Solutions, including lease transfers to stronger providers, which are expected to improve rent collection. “We’ve collected 72% of the contracted amount so far with Westmoreland, and we’re confident we’ll meet our target,” he said. Markham reviewed the FY24 results, noting that while net tangible assets declined to £0.99 per share, rent collection stood at 93% and the company maintains strong debt metrics with an average maturity of 8.6 years and a 2.74% all-in cost. For more updates like this, head to Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #SocialHousing #REIT #AtratoPartners #SOHO #SpecialisedSupportedHousing #IncomeSecurity #RealEstateInvestment #DividendStocks #UKHousing #InvestorUpdate #PropertyPortfolio #ESGInvesting

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

fink

Join the InvestorsHub Community

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

fink

Join the InvestorsHub Community

Join the InvestorsHub Community

Go Ad-Free